Transferrin-Conjugated Docetaxel–PLGA Nanoparticles for Tumor Targeting: Influence on MCF-7 Cell Cycle

por Jose, Sajan, Cinu, Thomas A., Sebastian, Rosmy, Shoja, M. H., Aleykutty, N. A., Durazzo, Alessandra, Lucarini, Massimo, Santini, Antonello, Souto, Eliana B.
Publicado 2019

Correction: Jose et al. Transferrin-Conjugated Docetaxel–PLGA Nanoparticles for Tumor Targeting: Influence on MCF-7 Cell Cycle. Polymers 2019, 11, 1905

por Jose, Sajan, Cinu, Thomas A., Sebastian, Rosmy, Shoja, M. H., Aleykutty, N. A., Durazzo, Alessandra, Lucarini, Massimo, Santini, Antonello, Souto, Eliana B.
Publicado 2022

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II

por Vieira, Raquel, Souto, Selma B., Sánchez-López, Elena, López Machado, Ana, Severino, Patricia, Jose, Sajan, Santini, Antonello, Silva, Amelia M., Fortuna, Ana, García, Maria Luisa, Souto, Eliana B.
Publicado 2019

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I

por Vieira, Raquel, Souto, Selma B., Sánchez-López, Elena, López Machado, Ana, Severino, Patricia, Jose, Sajan, Santini, Antonello, Fortuna, Ana, García, Maria Luisa, Silva, Amelia M., Souto, Eliana B.
Publicado 2019